Results 111 to 120 of about 4,340 (195)

New developments in the treatment of peripheral T-cell lymphoma – role of Belinostat

Cancer Management and Research, 2015
Peripheral T-cell lymphomas (PTCL) represent a heterogeneous group of rare malignancies that with the exception of anaplastic lymphoma kinase expressing anaplastic large cell lymphoma, share a poor outcome after standard (eg, anthracycline-based) chemotherapy. Most patients are either refractory to initial therapy or eventually relapse.
openaire   +4 more sources

IHC staining of transgenic mice bladders for , the cell proliferation marker Ki67 and , P21 in L-Arginine treated (left panel) and belinostat-treated bladder cancer mice (right panel)

, 2011
Copyright information:Taken from "The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo"http://www.translational-medicine.com/content/5/1/49Journal of Translational Medicine 2007;5():49-49 ...
Joanne Yoon (37162), Herman Yee (120), Xue-Ru Wu (37168), Michael T Buckley (37161), Leonard Liebes (119), Gulshan Ara (37164), Iman Osman (37169), Xiaozhong Qian (37165), Tung-Tien Sun (37167), Dean F Bajorin (37166), Luis Chiriboga (37163)   +10 more
core   +1 more source

Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts

, 2009
Belinostat is a hydroxamate-type histone deactylase inhibitor (HDACi), which has recently entered phase I and II clinical trials. Microarray-based analysis of belinostat-treated cell lines showed an impact on genes associated with the G2/M phase of the ...
Pezzoli, P., Monks, A., Shoemaker, R.H., Kondapaka, S., Hose, C.D., Sehested, M., Petersen, K.D., Vansant, G., Monforte, J.   +8 more
core  

Belinostat como tratamiento del linfoma de células T periférico recidivante: Revisión Sistemática

Título: Belinostat como tratamiento del linfoma de células T periférico recidivante: Revisión Sistemática Objetivo: El propósito de esta investigación es determinar la utilidad terapéutica del Belinostat en el linfoma de células T periférico recidivante.
Vera Arévalo , Daniela Anahí, Barrera Barrera , Erika Samantha   +1 more
core  

Screening and evaluation of potential histone deacetylase inhibitors against Babesia infections. [PDF]

Int J Parasitol Drugs Drug Resist
Zhang X, Li Y, Che J, Wang J, Liang Q, Zhang Y, Bai Y, Zhao S, Yin H, Wang J, Guan G.   +10 more
europepmc   +1 more source

[Corrigendum] 17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells. [PDF]

Oncol Rep
Zuo Y, Xu H, Chen Z, Xiong F, Zhang B, Chen K, Jiang H, Luo C, Zhang H.   +8 more
europepmc   +1 more source

GPX7 marks fibroblast-associated stromal-innate immune crosstalk in ulcerative colitis. [PDF]

Front Immunol
He J, Chen R, Qiu S, Li P, Gao X.
europepmc   +1 more source

FAME-CRISPR improves CRISPR-Cas9 genome editing via HDAC inhibition and engineered virus-like particle delivery. [PDF]

Cell Rep Methods
Djamshidi M, Hill A, Heshmatzad K, Langley J, Krowicki H, Ali M, Yang Y, Tanida R, Abdul-Careem MF, Billon P, Riabowol K.   +10 more
europepmc   +1 more source

Defining the heterogeneous molecular landscape of lung cancer cell responses to epigenetic inhibition. [PDF]

Commun Biol
Lin C, Sniezek CM, McGann CD, Karki R, Giglio RM, Garcia BA, McFaline-Figueroa JL, Schweppe DK.   +7 more
europepmc   +1 more source

Combining anti-gene γPNA with small molecules and RNA inhibitors: A strategy to enhance anti-tumor efficacy. [PDF]

Mol Ther Nucleic Acids
Pradeep SP, DiVasto BE, Glazer PM, Bahal R.   +3 more
europepmc   +1 more source